הכנסה תפעולית לפני ניכוי פחת: bluejaydx.com (BJDX)

Bluejay Diagnostics (BJDX) is implementing a digital IT platform to optimize the distribution of rapid tests, thereby increasing retail profitability. Current EBITDA figures illustrate profit sensitivity to market shocks, with 0.00 representing the latest level. Revenue is generated by Symphony system sales in cardiology centers, while the active promotion of this technology accelerates sepsis diagnosis directly at the patient's side.

This metric captures the net liquidity inflow from operating activities, excluding the impact of taxes and depreciation to assess the real cash efficiency of the business. The trend in absolute EBITDA levels demonstrates how successfully Bluejay Diagnostics (BJDX) monetizes the supply of rapid analyzers for intensive care units, converting the demand for sepsis diagnostics into actual growth of the company's cash reserves.